Search

Filters
Clear All
  • 8

Phase

  • 7
  • 8
  • 1

Found 8 Patrick Loehrer, MD trials

A listing of Patrick Loehrer, MD medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
All genders
The primary objective of this study is to obtain blood and tissue samples for laboratory evaluation.
Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab
All genders
This study involves standard combination chemotherapy treatment for colon cancer, 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus bevacizumab (Avastin). The study is designed to test the FOLFIRI regimen based on certain characteristics of a person's genetic makeup or "genes". Genes are made of DNA and determine not only …
Phase II Randomized Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198
All genders
The purpose of this study is to find out what effects, good and/or bad, there are to adding the drug ramucirumab (RAM) to the usual chemotherapy regimen.
Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
All genders
The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
All genders
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
All genders
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
Tissue Procurement Protocol for the Developmental Therapeutics Clinic National Cancer Institute (NCI)
All genders
The purpose of this study is to obtain samples for research purposes from tests performed for clinical indications or research indications on other research protocols, and to obtain samples for research purposes from non-surgical procedures, performed for the sole purpose of obtaining samples for this protocol.
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …